SCHEMBL556037

SCHEMBL556037

Cc1cc(O)n2nc(-c3ccccc3)c(Br)c2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
POLB P06746 2/20 0.52
GPR55 Q9Y2T6 1/20 0.50
MAPT P10636 7/20 0.44
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPK1 P28482 3/20 0.44
APOBEC3A P31941 2/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
KDM4E B2RXH2 7/20 0.43
HPGD P15428 3/20 0.42
ADORA2A P29274 1/20 0.41
USP2 O75604 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSD17B10 Q99714 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460193 0.77 L3MBTL1 (0.45) KMT2AMEN1POLBMAPTALDH1A1
SCHEMBL18004666 0.71 MAPT (0.51) KMT2AMEN1POLBMAPTALDH1A1
SCHEMBL7067985 0.70 MAPT (0.74) KMT2AMEN1POLBMAPTALDH1A1
SCHEMBL10408657 0.69 PDE10A (0.55) POLBMAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL13310492 0.69 MAPT (0.55) KMT2AMEN1POLBMAPTALDH1A1
SCHEMBL18189826 0.68 MEN1 (0.42) KMT2AMEN1POLBGPR55MAPT
SCHEMBL8822991 0.68 KMT2A (0.66) KMT2AMEN1POLBGPR55MAPT
SCHEMBL5391337 0.67 MAPT (0.49) KMT2AMEN1POLBGPR55MAPT
SCHEMBL14557189 0.67 AURKA (0.43) KMT2AMEN1POLBGPR55MAPT
SCHEMBL9738364 0.65 MEN1 (0.61) KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3569248-B1 GIP INHIBITORS FOR IMPROVING COGNITIVE FUNCTION KAO CORP (JP) 2023-12-06 EP claimed
EP-3560515-B1 GIP INHIBITORS FOR USE IN IMPROVING MOTOR CONTROL FUNCTION KAO CORP (JP) 2023-11-15 EP claimed
EP-3569248-A1 COGNITIVE FUNCTION IMPROVING AGENT Kao Corporation (JP) 2019-11-20 EP claimed
US-20190330333-A1 Cognitive Function Improving Agent KAO CORPORATION (JP) 2019-10-31 US claimed
US-20190330332-A1 Hypothermia Ameliorating Agent KAO CORPORATION (JP) 2019-10-31 US claimed
US-20190330334-A1 Motor Control Function Improving Agent KAO CORPORATION (JP) 2019-10-31 US claimed
EP-3560515-A1 MOTOR CONTROL FUNCTION IMPROVING AGENT Kao Corporation (JP) 2019-10-30 EP claimed
EP-3560514-A1 HYPOTHERMIA AMELIORATING AGENT Kao Corporation (JP) 2019-10-30 EP claimed
EP-3569248-B1 GIP INHIBITORS FOR IMPROVING COGNITIVE FUNCTION KAO CORP (JP) 2023-12-06 EP disclosed
EP-3560515-B1 GIP INHIBITORS FOR USE IN IMPROVING MOTOR CONTROL FUNCTION KAO CORP (JP) 2023-11-15 EP disclosed
US-11555069-B2 Cognitive function improving agent KAO CORPORATION (JP) 2023-01-17 US disclosed
US-11319369-B2 Motor control function improving agent KAO CORPORATION (JP) 2022-05-03 US disclosed
US-20210212959-A1 GIP ELEVATION INHIBITOR KAO CORPORATION (JP) 2021-07-15 US disclosed
EP-3797763-A1 GIP ELEVATION INHIBITOR Kao Corporation (JP) 2021-03-31 EP disclosed
EP-2011492-A1 GIP SECRETION INHIBITOR KAO CORPORATION (JP) 2009-01-07 EP disclosed
US-7081473-B2 Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2006-07-25 US disclosed
US-20050159415-A1 Agents for preventing or ameliorating insulin resistance and /or obesity SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2005-07-21 US disclosed
EP-1506777-A1 OBESITY PREVENTIVE OR AMELIORATOR CONTAINING METHYLIDENE HYDRAZIDE COMPOUND AS ACTIVE INGREDIENT Sanwa Kagaku Kenkyusho Co., Ltd. (JP) 2005-02-16 EP disclosed
US-20030157107-A1 Agents for preventing or ameliorating insulin resistance and/or obesity SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2003-08-21 US disclosed
EP-1283058-A1 AGENTS FOR PREVENTING OR AMELIORATING INSULIN RESISTANCE AND/OR OBESITY Sanwa Kagaku Kenkyusho Co., Ltd. (JP) 2003-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159415-A1 Agents for preventing or ameliorating insulin resistance and /or obesity GIPR, GPR119, GLP1R KMT2A 4550/4885MEN1 1087/4885POLB 4362/4885
US-20030157107-A1 Agents for preventing or ameliorating insulin resistance and/or obesity GIPR, GPR119, GLP1R KMT2A 4124/4885MEN1 1309/4885POLB 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.